Abstract. Intracerebral hemorrhage (ICH) is a life-threatening type of stroke. Previous studies have reported that bone marrow mesenchymal stem cells (BMSCs) may exert beneficial effects on the treatment of ICH. However, it remains unknown whether the neuroprotection exerted by BMSCs on ICH is due to the differentiation of BMSCs, or the trophic factors secreted into their conditioned medium (CM). In addition, growth-associated protein-43 (GAP-43) is a protein associated with neurite extension, which may be considered a prospective therapeutic target in the treatment of ICH. The present study investigated whether administration of BMSC-CM could be considered as an alternative to the established treatment of direct BMSC transplantation; in addition, the underlying mechanisms were evaluated. Neurological function tests, brain water content, reverse transcription -quantitative polymerase chain reaction and western blotting were used in present study. The current study indicated that the neuroprotective effects of BMSC implantation and BMSC-CM treatment are similar, and that both decrease the severity of post-ICH cerebral edema, as well as improving neurological functions. At the molecular level, treatment with BMSC-CM resulted in a marked elevation in the expression of GAP-43 and interleukin (IL)-10, in addition to a significant reduction in the expression levels of IL-1β, tumor necrosis factor-α and IL-6. Following application of a phosphorylated-extracellular signal-regulated kinase (ERK1/2) inhibitor, PD98059, in a BMSC-CM rat model, the mRNA and protein expression levels of GAP-43 were significantly attenuated. Therefore, the findings of the present study demonstrated that treatment with BMSC-CM may be an alternative to direct BMSC transplantation in a rat model of ICH. The mechanism underlying BMSC-CM-mediated neuroprotection may be associated with anti-inflammatory effects, as well as activation of GAP-43 transcription and expression through ERK-1/2 phosphorylation. Therefore, the ERK-1/2-GAP-43 signaling pathway may be considered a potential novel application target of BMSC-CM for the treatment of neurological diseases.
Introduction
Stroke is the fourth major cause of morbidity and remains a leading challenge to public health (1) . Intracerebral hemorrhage (ICH) is a life-threatening type of stroke that affects 2 million individuals annually worldwide (2) . The symptoms, which differ in accordance to the site and spectrum of brain damage, have the potential to be seriously disabling and may lead to impaired motor and sensorimotor functions, along with cognitive impairments (3) . ICH is characterized by extravasation of blood into the brain parenchyma, leading to hematoma formation, concomitant brain edema and secondary brain damage (4) . Previous studies regarding secondary brain damage have identified possible treatments that target brain edema, blood-brain barrier disruption, inflammation and the decomposition product of erythrocytes (5-7). However, despite considerable progress being made in animal models and preclinical research in recent years, there are currently no available therapeutic strategies in clinical practice for ICH (8) .
Growth-associated protein-43 (GAP-43) is a protein associated with neurite growth during development and regeneration, Intraparenchymal treatment with bone marrow mesenchymal stem cell-conditioned medium exerts neuroprotection following intracerebral hemorrhage which allows differentiating neurons to respond to extracellular signals of the central nervous system (CNS) (9) . A previous study demonstrated that mice lacking this protein have a low survival rate during the early postnatal period (10) . In human neuropathologies and their associated animal models, complex alterations in GAP-43 expression are frequently detected, suggesting axonal damage or attempts of regenerative axonal sprouting. A previous in vivo study demonstrated the requirement of GAP-43 in sustaining synaptic stability and accelerating the initiation of axonal regrowth (11) . In particular, one of the most marked regenerative events following the onset of stroke is axonal sprouting in the penumbra, which is accompanied by high expression of GAP-43 (12) (13) (14) . Therefore, it was hypothesized that GAP-43 may be a prospective therapeutic target for the treatment of ICH.
Bone marrow mesenchymal stem cells (BMSCs) are multipotent cells with self-renewal capabilities, which are able to differentiate into various cell types, including adipocytes, osteoblasts, chondroblasts and neural cells (15) (16) (17) . In addition, it has previously been indicated that BMSCs may modify the tissue microenvironment via secreting soluble factors to rejuvenate or reinstate diseased cells (18) . Such factors secreted from BMSCs serve a considerable role in various respects of hematopoiesis and are collectively termed trophic factors (19) . Therefore, BMSC-induced reinstating of dysfunctional tissues could result from secretion of these trophic factors and/or their differentiation. Previous studies have demonstrated that intraparenchymal transplantation of BMSCs can exert anti-inflammatory and regenerative effects, and ameliorate neurological deficits in numerous CNS diseases, including stroke (20) (21) (22) . However, the mechanisms by which BMSC implantation provides neuroprotection under CNS pathological circumstances are not well understood. Since transplantation of stem cells is often associated with poor differentiation and survival rates, utilization of conditioned medium (CM), which includes trophic factors from stem cells, has emerged as an alternative method (23, 24) . A recent study confirmed that CM from human umbilical cord MSCs has considerable potential for stroke treatment without requiring stem cell transplantation (25) . Therefore, the application of stem cell-CM in place of direct transplantation of stem cells may overcome the restrictions of current cell-based therapies. However, it remains unknown whether the therapeutic action of BMSCs is due to their differentiation or the trophic factors secreted into their CM.
In the present study, BMSC-CM was tested as an alternative to direct BMSC transplantation. To investigate the effects of BMSC-CM, the alterations in expression of GAP-43, phosphorylated-extracellular signal-regulated kinase (p-ERK1/2), p-c-Jun N-terminal kinase (JNK) and inflammatory factors [interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6 and IL-10] in the perihematomal tissues were assessed. The mechanisms underlying the effects of BMSC-CM were also examined, in order to identify whether it was associated with, at least in part, the secretion of neurotrophic factors that activate the ERK1/2 signaling pathway and thereby elevate GAP-43 expression.
Materials and methods

Animals.
All rat experiments were performed in compliance with the guidelines of the National Institutes of Health Guide (2011) for the Care and Use of Laboratory Animals (Bethesda, MD, USA). The present experimental procedures were approved by the Hebei Medical University Experimental Ethics Committee (Shijiazhuang, China). A total of 151 male Sprague-Dawley rats (8 weeks old; weight, 250-280 g) and 6 male Sprague-Dawley rats (3 weeks old; weight, 90-110 g) purchased from the Hebei United University Experimental Animal Center (Tangshan, China) were used in present study. Rats were anesthetized with 10% chloral hydrate (100 mg/kg, Bio-Rad Laboratories, Inc., Shanghai, China). All rats were maintained under a 12 h light/12 h dark cycle at 22-24˚C with ad libitum access to food and water. Great efforts were made to minimize the number of animals used and alleviate animal suffering.
Primary culture of BMSCs. BMSCs were generated from 6 male Sprague-Dawley rats (3 weeks old; weight, 90-110 g). The medullary cavities of rat femurs were flushed with Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) to collect fresh bone marrow cells. Cells were centrifuged at 1,000 x g for 5 min. Purified cells were dispersed in cell culture flasks at 37˚C (Corning Life Sciences, Tewksbury, MA, USA), and were cultured in DMEM supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37˚C in an atmosphere containing 5% CO 2 . After 48 h, non-adherent cells were removed and fresh media was added. Media was replaced every 3 days. After primary culturing, the cells were subcultured at a density of 1x10 4 cells/cm 2 and used for further experimentation after three passages.
Preparation of BMSC-CM.
BMSCs from three passages were cultured in culture flasks. When cells reached 80% confluence, they were cultured in 10 ml serum-free DMEM/F12. CM from BMSCs was collected after 1 day and centrifuged at 560 x g for 10 min at 37˚C. After the supernatants were re-centrifuged at 5,040 x g for 5 min at 37˚C, the CM was collected and used for further experimentation.
ICH model. The rat ICH model was established as described by a previous study (26) . Rats were anesthetized with an intraperitoneal injection of chloral hydrate (100 mg/kg body weight) and placed on stereotaxic apparatus. A hole was drilled into the skull, and a needle was inserted into the right basal ganglia under stereotactic guidance (coordinates: 0.2 mm anterior, 5.5 mm ventral, and 3.5 mm lateral to the midline). A total of 100 µl autologous arterial blood was infused slowly (5 µl/min) with a microinfusion pump. Following the completion of the infusion, the needle was left in place for 20 min prior to withdrawal. Control rats received an infusion of 100 µl normal saline. Bone wax was placed around the burr hole and all procedures were conducted under aseptic conditions to avoid infection.
Experiment groups.
Three experiments were performed as follows. Experiment 1 was conducted to determine the time course of brain water content and functional recovery. A total of 101 rats were randomly assigned to four groups: The normal control group (n=8, Sham); the ICH model group (n=31, ICH); the BMSC transplantation (10 µl, tail vein injection immediately post-ICH) after ICH group (n=31, BMSCs); and the BMSC-CM treatment (10 µl, tail vein injection immediately post-IC) after ICH group (n=31, CM). A forelimb-placing test, corner turn test and modified neurological severity score (mNSS) evaluation were used to detect motor and sensorimotor functions 1 day prior to and 1-7 days after surgery. The time course variation of brain edema was evaluated by analysis of brain water content 1-7 days following ICH. Cognitive impairment of the rats was evaluated by Morris water maze test 7-10 days following ICH.
Experiment 2 was conducted to identify the neuroprotective mechanism of BMSC-CM. A total of 30 rats were randomly divided into three groups: The sham-operated group (n=10, Sham); the ICH model group (n=10, ICH); and the BMSC-CM treatment after ICH group (n=10, CM). A total of 4 days after ICH or sham operation, reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis were used to detect the expression levels of axonal regrowth-associated protein GAP-43, p-ERK, p-JNK and inflammatory cytokines.
Experiment 3 was conducted to determine the regulation of GAP-43 transcription and expression following BMSC-CM treatment. A total of 20 ICH rats treated with BMSC-CM were randomly divided into two groups: The vehicle group, which received an equal volume of 5% dimethyl sulfoxide (DMSO; n=10, vehicle); and the PD98059 group, which received 5 µg p-ERK1/2 inhibitor PD98059 (Bio-Rad Laboratories, Inc.) dissolved in 5% DMSO (n=10, PD98059). The drug injection volume was 20 µl followed by a flush with 10 µl 0.9% saline via intrathecal injection 1 day after ICH.
Neurological function tests. Forelimb-placing test, corner turn test and an mNSS evaluation were performed prior to surgery and 1-7 days after ICH by an investigator who was blinded to the experimental groups. A total of 15 rats (5 per group) were used for these tests.
Forelimb placing was scored using a vibrissae-elicited forelimb-placing test. Independent testing of each forelimb was induced by brushing the vibrissae ipsilateral to that forelimb on the edge of a tabletop. Intact animals placed the forelimb quickly onto the countertop. This task was repeated 10 times and the percentage of successful placing responses was determined.
In the corner turn test, rats were allowed to proceed into a 30° corner. To exit the corner, the rat could turn either left or right, and the direction was recorded. This task was repeated 10 times.
The mNSS evaluation is a composite of motor, sensory, balance and reflex tests. Neurological function was graded on a scale of 0-18 (0, normal score; 18, maximal deficit score) with one point awarded for the exhibition of specific abnormal behavior or for lack of a tested reflex. A greater impairment of normal function results in a higher score.
Evaluation of brain edema. Brain edema was evaluated by analysis of brain water content, as previously described (27) . A total of 66 rats were used to evaluate brain edema (Sham, 3; ICH, 21; BMSCs, 21; CM, 21). The percentage of water in the tissues was calculated according to the following formula: Brain water %=[(wet weight-dry weight)/wet weight]x100.
Morris water maze test. The spatial learning and memory of the rats was evaluated by Morris water maze, as described previously, 7-10 days after ICH (28) . A total of 20 rats were used for this test (10 per group). Each rat was allowed to find the submerged platform within 60 sec. A total of 4 trials were conducted on the first testing day (7 days post-ICH), which was considered as a training procedure. Formal testing was then conducted daily on days 8, 9 and 10. At 5 h after the final testing on day 10, the platform was removed from the tank and a probe trial was performed to assess the learning and memory performance of each rat.
RT-PCR. Semi-quantitative PCR was conducted at 4 days post-ICH. Tissues were homogenized on ice with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and total RNA was extracted, according to the manufacturer's protocol. High-quality RNA was reverse transcribed into cDNA with a Reverse Transcription kit (Takara Biotechnology Co., Ltd., Dalian, China). GAP-43 and GAPDH primers were used. GAP-43 sense: 5'-CAT GAG AAG TAT GAC AAC AGC CT-3', GAP-43 antisense 5'-AGT CCT TCC ACG ATA CCA AAGT-3'; GAPDH sense: 5'-CTG CAA CCA AAA TTC AGG CTA-3', GAPDH antisense 5'-CAT CAG CAA CGG GAG CAT-3'. The PCR reaction system consisted of cDNA (10 ng), primers (0.1 µM), deoxy-ribonucleoside triphosphate (1 mM), Taq DNA polymerase (5 U), 10X buffer (2.5 µl), and double distilled water to a final volume of 25 µl. PCR amplification was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) on an ABI StepOnePlus Real-time PCR system (Thermo Fisher Scientific, Inc.). The PCR protocol was as follows: 95˚C for 2 min, 40 cycles of 95˚C for 10 sec and 60˚C for 40 sec. For semi-quantitative PCR, products were analyzed using agarose gel electrophoresis and the corresponding optical density ratio was quantified (optical density value of the specific gene/optical density value of GAPDH).
Western blot analysis. Western blotting was conducted at 4 days post-ICH. Rat perihematomal tissues were lysed in Tissue Protein Lysis Solution (Thermo Fisher Scientific, Inc.) supplemented with 5% Proteinase Inhibitor Cocktail (Sigma-Aldrich; Merck KGaA), incubated on ice for 30 min, and centrifuged at 15,000 x g at 22-24˚C for 15 min. Protein concentrations were determined using bicinchoninic acid protein assay reagents (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Samples were loaded (3 µl per line) onto 10% SDS-PAGE, and transferred to polyvinylidene difluoride membranes for 60 min. Non-specific binding sites were blocked with 5% bovine serum albumin (Bio-Rad Biotechnology, Inc.) at 22-24˚C for 1 h, then incubated with various antibodies: Rabbit anti-rat GAP-43 (cat. no. sc10786), IL-1β (cat. no. sc7884), IL-6 (cat. no. sc7920), IL-10 (cat. no. sc984), TNF-α (cat. no. sc8301), ERK (cat. no. sc292838), p-ERK (cat. no. sc101760), p-JNK (cat. no. sc135642) and β-actin (cat. no. sc130657) polyclonal antibodies (dilution, 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4˚C. The membranes were then incubated with secondary antibodies (cat. no. sc2955, dilution, 1:5,000; Santa Cruz Biotechnology, Inc.) for 2 h at 4˚C. The immunoreactive bands were visualized using an enhanced chemiluminescence reagent (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Blots were scanned by densitometry, and integrated density of pixels was quantified using Image Quant software (version, 5.2; Molecular Dynamics; GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).
Statistical analysis. Data are expressed as the mean ± standard error. All tests were performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). Statistical significance was determined using one-way analysis of variance, and the Student-Newman-Keuls post hoc test was used to determine differences among the groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Rat mortality. Only two of the total 151 rats succumbed during experimentation. One rat did not survive transplantation of BMSCs during experiment 1, and the other did not survive treatment with the vehicle in experiment 3.
Transplantation of BMSCs and BMSC-CM treatment ameliorates neurological deficit. Forelimb-placing and corner turn tests, and the mNSS evaluation, were performed prior to and 1-7 days after ICH. As presented in Fig. 1A , in the ICH model group, there was little recovery of forelimb placing with time. In the BMSC transplantation or BMSC-CM treatment groups, there was a significant recovery compared with in the ICH model group after 3-7 days (P<0.05 after 3 days; P<0.01 after 4-7 days). As depicted in Fig. 1B , in the corner turn test, the percentage of turns to the right was significantly decreased after 4-7 days in the BMSC transplantation and BMSC-CM treatment groups compared with in the ICH group (P<0.05 after 4-5 days; P<0.01 after 6-7 days). In addition, Fig. 1C demonstrated that transplantation of BMSCs or treatment with BMSC-CM resulted in significantly improved mNSS scores compared with in the ICH group after 4-7 days (P<0.01). However, there was no significant difference (P>0.05) in motor and sensorimotor functions after 1-7 days between the BMSCs and BMSC-CM groups (Fig. 1C) .
Transplantation of BMSCs and BMSC-CM treatment attenuates the extent of brain edema.
Analysis of brain water content was conducted 1-7 days post-ICH to identify the effects of BMSC transplantation and BMSC-CM on cerebral edema. As demonstrated in Fig. 2 , ICH caused a marked increase in brain water content compared with the sham-operated group (P<0.01). The mean brain water content of rat brains was significantly increased in the ICH group compared with in the BMSCs or BMSC-CM groups after 3-5 days (P<0.01). However, there was no significant difference (P>0.05) in brain water content after 1-7 days between the BMSCs and BMSC-CM groups.
Transplantation of BMSCs or BMSC-CM treatment has no effect on ICH-induced cognitive function deficits.
To determine whether BMSC transplantation and BMSC-CM treatment led to improved cognitive functional outcome post-ICH, a Morris water maze study was conducted 7-10 days after ICH (Fig. 3) . Fig. 3A illustrates the effects of BMSC transplantation and BMSC-CM on latency time for finding the hidden platform during latency trials. Latency time in the ICH groups was progressively longer compared with in the sham group, in a time-dependent manner; however, there was no significant difference between the ICH, BMSCs and BMSC-CM treatment groups. Representative trace diagrams indicating the latency time for finding the submerged platform on day 10 are depicted in Fig. 3Da-d . In probe trials, which are characterized by the removal of the hidden platform ( Fig. 3B and C) , ICH rats displayed a reduced bias towards the goal quadrant, which previously contained the platform. They spent less time in the goal quadrant and had less platform crossings compared with their sham counterparts. In addition, this phenomenon was not altered in the BMSCs and BMSC-CM groups. Representative traces obtained during the specified probe trials are depicted in Fig. 3De-h. 
BMSC-CM treatment reduces the expression of IL-1β, IL-6 and TNF-α, but not IL-10, in perihematomal tissues.
To explore the anti-inflammatory effects of BMSC-CM treatment on ICH, the expression levels of inflammatory cytokines, including TNF-α, IL-1β and IL-6, and the anti-inflammatory cytokine IL-10, were measured 4 days after ICH in the perihematomal tissues by western blot analysis. As demonstrated in Fig. 4 , the protein expression levels of IL-1β, IL-6 and TNF-α were significantly reduced in the brains of BMSC-CM-treated rats compared with in the ICH group (IL-6 and TNF-α, P<0.01; IL-1β, P<0.05). Conversely, the expression levels of IL-10 were increased compared with in the ICH group (P<0.01).
BMSC-CM treatment enhances phosphorylation of ERK1/2 in perihematomal tissues.
The present study explored whether BMSC-CM treatment could enhance the activation of cell signaling. As demonstrated in Fig. 5 , phosphorylation of ERK1/2 and JNK was significantly elevated in the perihematomal region 4 days after ICH (P<0.01), whereas BMSC-CM treatment further enhanced ERK1/2 phosphorylation (Fig. 5B,  P<0 .01). However, BMSC-CM treatment had no effect on JNK activation in the perihematomal region 4 days after ICH (Fig. 5C, P>0 .05).
BMSC-CM rescues GAP-43 transcription and expression in perihematomal tissues.
To determine the effects of BMSC-CM on GAP-43 transcription and expression post-ICH, the expression levels of GAP-43 were detected by RT-PCR and western blot analysis. RT-PCR (Fig. 6A ) demonstrated that the mRNA expression levels of GAP-43 in the ICH group were markedly increased 4 days following the operation (P<0.01). In the CM group, BMSC-CM treatment significantly enhanced the mRNA expression levels of GAP-43 compared with in the ICH rats (P<0.01). The results of western blot analysis (Fig. 6B) indicated that ICH induced the elevation of GAP-43 protein compared with the Sham group (P<0.01), and the expression of GAP-43 was markedly reinforced following BMSC-CM treatment (P<0.01).
PD98059 reverses the elevation of GAP-43 transcription and expression following BMSC-CM treatment in perihematomal tissues.
To further investigate whether the activation of GAP-43 following BMSC-CM treatment was regulated by the ERK1/2 signaling pathway, a p-ERK1/2 inhibitor, PD98059, was intrathecally administered. Fig. 7 depicts the alterations in inflammatory cytokine level, cell signaling, and GAP-43 transcription and expression following the administration of PD98059 4 days after ICH. Notably, PD98059 inhibited the phosphorylation of ERK1/2 (Fig. 7F, P<0.01) . The mRNA and protein expression levels of GAP-43 were also significantly decreased in the PD598059 group compared with in the vehicle group (Fig. 7H and J, P<0 .01). However, there was no significant difference (P>0.05) in the expression of inflammatory cytokines between the vehicle and PD98059 treatment groups.
Discussion
The present study demonstrated that intraparenchymal treatment with BMSC-CM 1 day after ICH exerted neuroprotective effects in rats. Treatment with BMSC-CM attenuated post-ICH cerebral edema after 3-5 days and improved the motor functions of ICH rats after 3-7 days. Furthermore, the current study investigated the mechanisms underlying the protective effects of BMSC-CM on ICH. At the molecular level, the expression levels of GAP-43 and inflammatory cytokines in the perihematomal tissues were detected 4 days after ICH. Treatment with BMSC-CM resulted in a marked elevation in the expression of GAP-43 and IL-10, as well as a significant reduction in the expression levels of IL-1β, TNF-α and IL-6. These findings suggested that BMSC-CM acts by inhibiting neuroinflammatory activation, and regulating the expression of GAP-43. Following administration of the p-ERK1/2 inhibitor, PD98059, in BMSC-CM-treated rats, the mRNA and protein expression levels of GAP-43 were significantly decreased, suggesting that the ERK1/2 signaling pathway is essential for GAP-43 expression. A previous study reported that CM from human adipose-derived MSCs mediated protection in neurons following glutamate excitotoxicity by regulating energy metabolism and GAP-43 expression (29) . In addition, a recent in vivo study demonstrated that CM from human umbilical cord MSCs contributed to vascular remodeling in the ischemic brain, which serves an important role in functional outcome in a rat model of stroke (25) . These findings, together with the observations of the present study, may aid to improve current understanding regarding stem cell-CM-mediated neuroprotection in neurological disorders.
ICH has a complex pathology with numerous diverse and incompletely clarified etiologies and prognoses. Despite various promising preclinical experiments, including the evaluation of anti-inflammatory, anti-hypertensive and neuroprotective drugs, only symptomatic treatments are currently effective (8) . In this context, the search for novel alternatives is a necessity for ICH treatment. A previous study regarding stem cell transplantation in ICH animal models demonstrated that transplantation attenuated hematoma and improved neurological behaviors (30) . Among miscellaneous stem cells, neural stem cells (NSCs) and MSCs are the most widely used and are considered promising in the treatment of ICH. As a result of the distinct capacity of NSCs to differentiate into functional neural cells, the neuroprotective effect may result from transplantation of NSCs replacing damaged neurons. Conversely, the efficacy of MSCs, as demonstrated in models of neurological disease, may be due to the cells' capacity to secrete various neurotrophins, such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), all of which potentially contribute to functional recovery following ICH (31-33). In particular, BMSCs have been regarded as candidates for cell therapy as they can express an extensive ability for expansion in vitro and can be readily procured by a simple bone marrow aspiration (34) . The present study indicated that the neuroprotective effects of BMSC implantation and BMSC-CM treatment have no significant difference to each other and both prevent post-ICH cerebral edema and improve neurological function. Therefore, the observed beneficial effects of BMSCs are mediated by soluble factors secreted by these BMSCs into CM.
The present results also suggested that BMSC-CM was able to exert anti-inflammatory effects in perihematomal tissues of ICH rats. Previous studies have focused on therapies for secondary brain injury following ICH and indicated that inflammatory events within the first 7 days are the crucial contributor to secondary brain injury (20, 35) . These findings indicated that attenuation of inflammatory factors may improve neurological recovery following ICH. It has been demonstrated that inflammatory cytokines, including TNF-α, IL-1β and IL-6, produce cerebral edema and brain damage post-ICH by recruiting lymphocyte and neutrophil infiltration into perihematomal tissues (20, 36, 37) . Conversely, the anti-inflammatory cytokine IL-10 exerts beneficial effects against brain damages post-ICH (38) . A previous study indicated that compared with the pathophysiology of traumatic brain injury and cerebral ischemia, the pathophysiology of ICH was not associated with the expression of TNF-α, IL-1β and IL-6 in the acute phase (1 h after ICH) in the perihematomal region (35) . In the present study, 4 days after ICH, TNF-α, IL-1β and IL-6 levels were decreased, whereas IL-10 expression was significantly elevated in the perihematomal tissues of BMSC-CM-treated rats. These results provided evidence to suggest that BMSC-CM is able to effectively regulate the production and secretion of inflammatory cytokines in the perihematomal regions of the ICH-injured brain.
The present study focused on the association between ERK1/2 signaling and GAP-43 transcription and expression. It appears that the phosphorylation of ERK1/2 is a major mechanism in BMSC-CM-induced GAP-43 expression in ICH rats. A previous study suggested that GAP-43 was required for BDNF-induced ERK1/2 activation (39). The findings of the present study, together with previous hypotheses, highlight the possibility that heterogeneous factors, including BDNF, NGF and VEGF, are involved in a similar signaling pathway leading to ERK1/2 phosphorylation (40) . To the best of our knowledge, the present study is the first to suggest that the ERK1/2-GAP-43 signaling pathway may be considered a potential novel application target of BMSC-CM for the treatment of CNS diseases.
In addition to motor deficits post-ICH, learning and memory impairments may evolve that also adversely impair lifestyle (41) . Previous studies have confirmed the role of the striatum in cognition, and extravasation of blood into the caudate putamen of rats produces a learning and memory impairment (42, 43) . In the present study, the rat cognitive test was conducted 7-10 days after ICH. BMSC transplantation and BMSC-CM treatment produced no significant effect on the learning and memory functions of ICH rats. However, it remains uncertain as to whether BMSC or BMSC-CM treatment has beneficial effects on learning and memory functions in the ICH model used in the present study, since the study was conducted during a relatively short time period. In addition, the majority of patients with ICH are elderly; however, the rats used in the present study were selected from a fixed age group with a high proportion of young rats. Therefore, future studies are required to explore the long-term effects of BMSC-CM-mediated neuroprotection in aged animal models.
In conclusion, treatment with BMSC-CM may be considered an alternative to direct BMSC transplantation in a rat model of ICH. The mechanism underlying BMSC-CM-mediated neuroprotection may involve anti-inflammatory effects, and activation of GAP-43 transcription and expression via ERK1/2 phosphorylation. 
